USANA Fourth Quarter Net Sales Fall 15 Percent to 228 Million; Reiterates 2023 Outlook

SALT LAKE CITY, February 7, 2023 -- USANA Health Sciences reported fourth-quarter 2022 net sales of 228 million dollars, down 15 percent from 267 million dollars a year earlier, and diluted EPS of 0.66 dollars compared with 1.03 dollars. Full-year net sales were 999 million dollars, down 16 percent from 1.186 billion dollars, and diluted EPS was 3.59 dollars versus 5.73 dollars.

Active customers ended the year at 490,000, down 13 percent year over year but up 3 percent sequentially. Asia Pacific contributed 183 million dollars, or about 80 percent of quarterly sales, including 118 million dollars from Greater China. The company ended the year with 288 million dollars in cash and no debt, and generated 104 million dollars of operating cash flow in 2022.

USANA reiterated fiscal 2023 outlook of 850 million to 950 million dollars in net sales and 2.35 to 3.30 dollars in diluted EPS. Chief executive Kevin Guest said results were largely in line with the January 5 preliminary release and that strategies focus on growing active customers through live events, market expansion, incentives and acquisitions.